We use cookies to improve your browsing experience and provide meaningful content. Read our cookie policy. Accept
  •  Customer Login
  • Register
  •  View Cart (0)
  •  Customer Login
  • Register
  •  View Cart (0)

Takara Bio
  • Products
  • Services & Support
  • Learning centers
  • APPLICATIONS
  • About
  • Contact Us

Clontech Takara Cellartis

Close

  • ‹ Back to Legacy RNA-seq kits
  • SMART-Seq Stranded for total RNA-seq
  • Pico-input strand-specific total RNA-seq for mammalian samples v2
  • Pico-input strand-specific total RNA-seq for mammalian samples v3
  • SMART-Seq Single Cell for scRNA-seq
  • SMART-Seq v4 for mRNA-seq
  • SMART-Seq HT for streamlined mRNA-seq
  • Low-input strand-specific total RNA-seq for mammalian samples
  • High-input strand-specific total RNA-seq for mammalian samples
  • Stranded RNA-seq for nonmammalian samples
  • SMART-Seq v4 for mRNA-seq with the Fluidigm C1
  • SMARTer RNA Unique Dual Index Kits
  • Other legacy kits
RNA-seq selection guide
Technical notes View data for this product
Technical notes View data for FFPE samples
Home › Products › Next-generation sequencing › RNA-seq › Legacy RNA-seq kits › Pico-input strand-specific total RNA-seq for mammalian samples v2

RNA-seq

  • mRNA-seq
    • Long-read mRNA-seq
    • Full-length mRNA-seq
      • SMART-Seq mRNA Single Cell LP and SMART-Seq mRNA Single Cell
      • SMART-Seq mRNA LP and SMART-Seq mRNA
      • SMART-Seq mRNA HT and SMART-Seq mRNA HT LP
    • Full-length mRNA-seq and RNA counting with UMIs
    • 3’ Differential Expression
    • Target capture
  • Total RNA-seq
    • SMART-Seq Total RNA-Seq Single Cell (ZapR Mammalian)
    • SMART-Seq Total RNA Pico Input with UMIs (ZapR Mammalian)
    • SMART-Seq Total RNA Pico Input (ZapR Mammalian)
    • SMART-Seq Total RNA Mid Input
    • SMART-Seq Total RNA High Input (RiboGone Mammalian)
  • RNA-seq accessories
    • Ribosomal RNA removal
    • Single-cell lysis buffer
  • Legacy RNA-seq kits
    • SMART-Seq Stranded for total RNA-seq
    • Pico-input strand-specific total RNA-seq for mammalian samples v2
    • Pico-input strand-specific total RNA-seq for mammalian samples v3
    • SMART-Seq Single Cell for scRNA-seq
    • SMARTer RNA Unique Dual Index Kits
Need help?
Contact Sales
RNA-seq selection guide
Technical notes View data for this product
Technical notes View data for FFPE samples

SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

NOTE: For RNA sequencing with picogram sample inputs, we recommend the reconfigured version of the kit below, SMART-Seq Total RNA Pico Input (ZapR Mammalian) (Cat. # 634357, 634358 & 634359).

SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (Cat. # 634411, 634412, 634413, 634414, 634417 & 634418) will be phased out within a year. Contact your local sales representative for more information.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is designed for efficient preparation of Illumina sequencing libraries from picogram input amounts (250 pg–10 ng) of total RNA. Technologies included in this product enable processing of high-quality, partially degraded, or low-quality RNA, including RNA prepared from FFPE or LCM samples.

NOTE: For RNA sequencing with picogram sample inputs, we recommend the reconfigured version of the kit below, SMART-Seq Total RNA Pico Input (ZapR Mammalian) (Cat. # 634357, 634358 & 634359).

SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (Cat. # 634485, 634486, 634487 & 634488) will be phased out within a year. Contact your local sales representative for more information.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is designed for efficient preparation of Illumina sequencing libraries from picogram input amounts (250 pg–10 ng) of total RNA. Technologies included in this product enable processing of high-quality, partially degraded, or low-quality RNA, including RNA prepared from FFPE or LCM samples. The kit features a streamlined workflow that retains strand information and includes library prep by incorporating indexes and adapters during the reverse-transcription and PCR-amplification steps. This updated version of our original SMARTer kit for picogram inputs includes refinements that provide improved sequencing performance on all Illumina platforms and a more user-friendly library-purification workflow. The entire protocol, including library prep and purification, takes only about 6 hours.

Ribosomal RNA (rRNA) comprises a significant proportion (as much as 90%) of total RNA samples. Depleting these abundant transcripts from total RNA prior to library construction provides benefits by lowering sequencing costs and improving mapping statistics. However, with very low input amounts, rRNA depletion from total RNA leaves an insufficient amount of material for the preparation of a high-quality library. The workflow used in this kit incorporates a proprietary technology that depletes ribosomal cDNA (cDNA fragments originating from rRNA molecules) using probes specific to mammalian rRNA and some mitochondrial RNA.

Libraries produced with this kit are configured differently than libraries generated with the previous version, such that they achieve a high percentage of clusters passing filter (%PF) without significant additions of PhiX, even on Illumina platforms using two-channel SBS technology such as NextSeq® and MiniSeq™, and on HiSeq® 3000/4000. This, in turn, reduces sequencing costs by yielding more biologically relevant sequencing reads per run. Data from the Pico v2 kit also tends to identify more unique transcripts with fewer reads mapping to rRNA and mtRNA and lower duplicate rates. Furthermore, the Pico v2 kit includes a new PCR buffer formulation that increases the efficiency of library purification.

This kit is available in 12-, 48-, 96-, and 192-reaction sizes.  High-throughput versions of the kit (Cat. Nos. 634413 & 634414) include 12 different reverse primers and 8 different forward primers, allowing library construction with up to 96 different combinations of Illumina indexes.

To allow additional customization and flexibility, we also offer the 96- and 192-reaction sizes of this kit without indexing primers (Cat. Nos. 634418 & 634419). These kits can be used with our SMARTer RNA Unique Dual Index Kits (Cat. Nos. 634451, 634452 & 634457), which are sold separately.

Alternate kits for other input amounts and options:

  • For 10–100 ng of total RNA, we recommend SMART-Seq Total RNA Mid Input
  • For 100 ng–1 µg of total RNA, we recommend SMART-Seq Total RNA High Input (RiboGone Mammalian)
 More  Less
Cat. # Product Size Price License Quantity Details
634411 SMARTer® Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian 12 Rxns USD $1198.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian improves sequencing performance compared to the original SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, particularly for NextSeq® and MiniSeq™ instruments carrying the two-channel SBS technology. This kit includes the Indexing Primer Set HT for Illumina v2; for your convenience, we also offer the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components (Cat. #s 634418 and 634419) without indexing primers.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Structural features of final libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. The adapters added using 5' PCR Primer HT and 3' PCR Primer HT contain sequences allowing clustering on any Illumina® flow cell (P7 shown in light blue, P5 shown in red), Illumina TruSeq® HT indexes (Index 1 [i7] sequence shown in orange, and Index 2 [i5] sequence shown in yellow), as well as the regions recognized by sequencing primers Read Primer 2 (Read 2, purple) and Read Primer 1 (Read 1, green). Read 1 generates sequences antisense to the original RNA, while Read 2 yields sequences sense to the original RNA (orientation of original RNA denoted by 5' and 3' in dark blue). The first three nucleotides of the second sequencing read (Read 2) are derived from the Pico v2 SMART Adapter (shown as Xs). These three nucleotides must be trimmed prior to mapping if performing paired-end sequencing.

Back

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved pass-filter rates (%PF) with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Libraries generated with the Pico v1 or Pico v2 kits were pooled and run on NextSeq 500 or MiniSeq instruments, as indicated. For each graph, blue boxplots indicate the distribution of cluster densities for unfiltered (i.e., raw) reads, while the green boxplots indicate the distribution of cluster densities for reads that passed filtering. Quantities of reads passing filter (in millions) and %PF values for each sequencing run are included above each graph. The expected number of reads passing filter according to Illumina specifications was 130 million reads for runs on the NextSeq and 25 million reads for runs on the MiniSeq. Proportions of reads that aligned to PhiX sequences ranged from 0.5% to 1.15% for all sequencing runs. As indicated in the graphs, libraries generated with the Pico v2 kit achieved higher %PF values for both Illumina platforms relative to libraries generated with the Pico v1 kit, and yielded quantities of reads passing filter that greatly exceeded the Illumina specifications.

Back

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of technology in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. SMART technology is used in this ligation-free protocol to preserve strand-of-origin information. Random priming (represented as the green N6 Primer) allows the generation of cDNA from all RNA fragments in the sample, including rRNA. When the SMARTScribe Reverse Transcriptase (RT) reaches the 5' end of the RNA fragment, the enzyme’s terminal transferase activity adds a few non-templated nucleotides to the 3' end of the cDNA (shown as Xs). The carefully designed Pico v2 SMART Adapter (included in the SMART TSO Mix v2) base-pairs with the non-templated nucleotide stretch, creating an extended template to enable the RT to continue replicating to the end of the oligonucleotide. The resulting cDNA contains sequences derived from the random primer and the Pico v2 SMART Adapter used in the reverse transcription reaction. In the next step, a first round of PCR amplification (PCR1) adds full-length Illumina adapters, including barcodes. The 5' PCR Primer binds to the Pico v2 SMART Adapter sequence (light purple), while the 3' PCR Primer binds to sequence associated with the random primer (green). The ribosomal cDNA (originating from rRNA) is then cleaved by ZapR v2 in the presence of the mammalian-specific R-Probes v2. This process leaves the library fragments originating from non-rRNA molecules untouched, with priming sites available on both 5' and 3' ends for further PCR amplification. These fragments are enriched via a second round of PCR amplification (PCR2) using primers universal to all libraries. The final library contains sequences allowing clustering on any Illumina flow cell.

Back

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sensitivity and reproducibility with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Sequencing libraries were generated from 1 ng and 10 ng inputs of total RNA extracted from human lung FFPE tissue using both the Pico v1 and Pico v2 kits, and sequenced on a NextSeq 500 instrument. Panel A. Sequencing metrics for libraries generated from 1 ng or 10 ng inputs using each kit. For both input amounts, the Pico v2 kit resulted in greater library yields, a lower proportion of reads mapping to rRNA and mtRNA, and a lower duplicate rate. For the 1 ng input, sequencing data from the Pico v2 library also identified thousands more transcripts than sequencing data from the Pico v1 library, indicating a higher sensitivity for Pico v2. Panel B. Comparison of transcript expression levels across input amounts. Higher reproducibility was observed between 1 ng and 10 ng inputs for data generated with the Pico v2 kit vs. data generated using the Pico v1 kit. FPKM values are shown on a Log10 scale. Transcripts represented in only one library can be seen along the X- and Y-axes of the scatter plots.

Back

SeqAmp CB PCR buffer improves bead-pellet formation

SeqAmp CB PCR buffer improves bead-pellet formation

Improved bead-pellet formation with new SeqAmp CB PCR buffer. The PCR buffer included in the Pico v2 kit was re-formulated to allow for faster, tighter bead-pellet formation. Following magnetic separation for a fixed period, bead pellets formed in the new SeqAmp CB buffer (right) are tighter than those formed in the original PCR buffer (left). Tighter bead pellets tend to dry more evenly and are easier to resuspend than pellets that are broader and more diffuse.

Back

634411: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

634411: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian
634412 SMARTer® Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian 48 Rxns USD $3966.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian improves sequencing performance compared to the original SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, particularly for NextSeq® and MiniSeq™ instruments carrying the two-channel SBS technology. This kit includes the Indexing Primer Set HT for Illumina v2; for your convenience, we also offer the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components (Cat. #s 634418 and 634419) without indexing primers.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634412: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

634412: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Back

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Structural features of final libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. The adapters added using 5' PCR Primer HT and 3' PCR Primer HT contain sequences allowing clustering on any Illumina® flow cell (P7 shown in light blue, P5 shown in red), Illumina TruSeq® HT indexes (Index 1 [i7] sequence shown in orange, and Index 2 [i5] sequence shown in yellow), as well as the regions recognized by sequencing primers Read Primer 2 (Read 2, purple) and Read Primer 1 (Read 1, green). Read 1 generates sequences antisense to the original RNA, while Read 2 yields sequences sense to the original RNA (orientation of original RNA denoted by 5' and 3' in dark blue). The first three nucleotides of the second sequencing read (Read 2) are derived from the Pico v2 SMART Adapter (shown as Xs). These three nucleotides must be trimmed prior to mapping if performing paired-end sequencing.

Back

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved pass-filter rates (%PF) with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Libraries generated with the Pico v1 or Pico v2 kits were pooled and run on NextSeq 500 or MiniSeq instruments, as indicated. For each graph, blue boxplots indicate the distribution of cluster densities for unfiltered (i.e., raw) reads, while the green boxplots indicate the distribution of cluster densities for reads that passed filtering. Quantities of reads passing filter (in millions) and %PF values for each sequencing run are included above each graph. The expected number of reads passing filter according to Illumina specifications was 130 million reads for runs on the NextSeq and 25 million reads for runs on the MiniSeq. Proportions of reads that aligned to PhiX sequences ranged from 0.5% to 1.15% for all sequencing runs. As indicated in the graphs, libraries generated with the Pico v2 kit achieved higher %PF values for both Illumina platforms relative to libraries generated with the Pico v1 kit, and yielded quantities of reads passing filter that greatly exceeded the Illumina specifications.

Back

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of technology in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. SMART technology is used in this ligation-free protocol to preserve strand-of-origin information. Random priming (represented as the green N6 Primer) allows the generation of cDNA from all RNA fragments in the sample, including rRNA. When the SMARTScribe Reverse Transcriptase (RT) reaches the 5' end of the RNA fragment, the enzyme’s terminal transferase activity adds a few non-templated nucleotides to the 3' end of the cDNA (shown as Xs). The carefully designed Pico v2 SMART Adapter (included in the SMART TSO Mix v2) base-pairs with the non-templated nucleotide stretch, creating an extended template to enable the RT to continue replicating to the end of the oligonucleotide. The resulting cDNA contains sequences derived from the random primer and the Pico v2 SMART Adapter used in the reverse transcription reaction. In the next step, a first round of PCR amplification (PCR1) adds full-length Illumina adapters, including barcodes. The 5' PCR Primer binds to the Pico v2 SMART Adapter sequence (light purple), while the 3' PCR Primer binds to sequence associated with the random primer (green). The ribosomal cDNA (originating from rRNA) is then cleaved by ZapR v2 in the presence of the mammalian-specific R-Probes v2. This process leaves the library fragments originating from non-rRNA molecules untouched, with priming sites available on both 5' and 3' ends for further PCR amplification. These fragments are enriched via a second round of PCR amplification (PCR2) using primers universal to all libraries. The final library contains sequences allowing clustering on any Illumina flow cell.

Back

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sensitivity and reproducibility with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Sequencing libraries were generated from 1 ng and 10 ng inputs of total RNA extracted from human lung FFPE tissue using both the Pico v1 and Pico v2 kits, and sequenced on a NextSeq 500 instrument. Panel A. Sequencing metrics for libraries generated from 1 ng or 10 ng inputs using each kit. For both input amounts, the Pico v2 kit resulted in greater library yields, a lower proportion of reads mapping to rRNA and mtRNA, and a lower duplicate rate. For the 1 ng input, sequencing data from the Pico v2 library also identified thousands more transcripts than sequencing data from the Pico v1 library, indicating a higher sensitivity for Pico v2. Panel B. Comparison of transcript expression levels across input amounts. Higher reproducibility was observed between 1 ng and 10 ng inputs for data generated with the Pico v2 kit vs. data generated using the Pico v1 kit. FPKM values are shown on a Log10 scale. Transcripts represented in only one library can be seen along the X- and Y-axes of the scatter plots.

Back

SeqAmp CB PCR buffer improves bead-pellet formation

SeqAmp CB PCR buffer improves bead-pellet formation

Improved bead-pellet formation with new SeqAmp CB PCR buffer. The PCR buffer included in the Pico v2 kit was re-formulated to allow for faster, tighter bead-pellet formation. Following magnetic separation for a fixed period, bead pellets formed in the new SeqAmp CB buffer (right) are tighter than those formed in the original PCR buffer (left). Tighter bead pellets tend to dry more evenly and are easier to resuspend than pellets that are broader and more diffuse.

634413 SMARTer® Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian 96 Rxns USD $5216.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian improves sequencing performance compared to the original SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, particularly for NextSeq® and MiniSeq™ instruments carrying the two-channel SBS technology. This kit includes the Indexing Primer Set HT for Illumina v2; for your convenience, we also offer the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components (Cat. #s 634418 and 634419) without indexing primers.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634413: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

634413: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Back

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Structural features of final libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. The adapters added using 5' PCR Primer HT and 3' PCR Primer HT contain sequences allowing clustering on any Illumina® flow cell (P7 shown in light blue, P5 shown in red), Illumina TruSeq® HT indexes (Index 1 [i7] sequence shown in orange, and Index 2 [i5] sequence shown in yellow), as well as the regions recognized by sequencing primers Read Primer 2 (Read 2, purple) and Read Primer 1 (Read 1, green). Read 1 generates sequences antisense to the original RNA, while Read 2 yields sequences sense to the original RNA (orientation of original RNA denoted by 5' and 3' in dark blue). The first three nucleotides of the second sequencing read (Read 2) are derived from the Pico v2 SMART Adapter (shown as Xs). These three nucleotides must be trimmed prior to mapping if performing paired-end sequencing.

Back

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved pass-filter rates (%PF) with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Libraries generated with the Pico v1 or Pico v2 kits were pooled and run on NextSeq 500 or MiniSeq instruments, as indicated. For each graph, blue boxplots indicate the distribution of cluster densities for unfiltered (i.e., raw) reads, while the green boxplots indicate the distribution of cluster densities for reads that passed filtering. Quantities of reads passing filter (in millions) and %PF values for each sequencing run are included above each graph. The expected number of reads passing filter according to Illumina specifications was 130 million reads for runs on the NextSeq and 25 million reads for runs on the MiniSeq. Proportions of reads that aligned to PhiX sequences ranged from 0.5% to 1.15% for all sequencing runs. As indicated in the graphs, libraries generated with the Pico v2 kit achieved higher %PF values for both Illumina platforms relative to libraries generated with the Pico v1 kit, and yielded quantities of reads passing filter that greatly exceeded the Illumina specifications.

Back

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of technology in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. SMART technology is used in this ligation-free protocol to preserve strand-of-origin information. Random priming (represented as the green N6 Primer) allows the generation of cDNA from all RNA fragments in the sample, including rRNA. When the SMARTScribe Reverse Transcriptase (RT) reaches the 5' end of the RNA fragment, the enzyme’s terminal transferase activity adds a few non-templated nucleotides to the 3' end of the cDNA (shown as Xs). The carefully designed Pico v2 SMART Adapter (included in the SMART TSO Mix v2) base-pairs with the non-templated nucleotide stretch, creating an extended template to enable the RT to continue replicating to the end of the oligonucleotide. The resulting cDNA contains sequences derived from the random primer and the Pico v2 SMART Adapter used in the reverse transcription reaction. In the next step, a first round of PCR amplification (PCR1) adds full-length Illumina adapters, including barcodes. The 5' PCR Primer binds to the Pico v2 SMART Adapter sequence (light purple), while the 3' PCR Primer binds to sequence associated with the random primer (green). The ribosomal cDNA (originating from rRNA) is then cleaved by ZapR v2 in the presence of the mammalian-specific R-Probes v2. This process leaves the library fragments originating from non-rRNA molecules untouched, with priming sites available on both 5' and 3' ends for further PCR amplification. These fragments are enriched via a second round of PCR amplification (PCR2) using primers universal to all libraries. The final library contains sequences allowing clustering on any Illumina flow cell.

Back

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sensitivity and reproducibility with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Sequencing libraries were generated from 1 ng and 10 ng inputs of total RNA extracted from human lung FFPE tissue using both the Pico v1 and Pico v2 kits, and sequenced on a NextSeq 500 instrument. Panel A. Sequencing metrics for libraries generated from 1 ng or 10 ng inputs using each kit. For both input amounts, the Pico v2 kit resulted in greater library yields, a lower proportion of reads mapping to rRNA and mtRNA, and a lower duplicate rate. For the 1 ng input, sequencing data from the Pico v2 library also identified thousands more transcripts than sequencing data from the Pico v1 library, indicating a higher sensitivity for Pico v2. Panel B. Comparison of transcript expression levels across input amounts. Higher reproducibility was observed between 1 ng and 10 ng inputs for data generated with the Pico v2 kit vs. data generated using the Pico v1 kit. FPKM values are shown on a Log10 scale. Transcripts represented in only one library can be seen along the X- and Y-axes of the scatter plots.

Back

SeqAmp CB PCR buffer improves bead-pellet formation

SeqAmp CB PCR buffer improves bead-pellet formation

Improved bead-pellet formation with new SeqAmp CB PCR buffer. The PCR buffer included in the Pico v2 kit was re-formulated to allow for faster, tighter bead-pellet formation. Following magnetic separation for a fixed period, bead pellets formed in the new SeqAmp CB buffer (right) are tighter than those formed in the original PCR buffer (left). Tighter bead pellets tend to dry more evenly and are easier to resuspend than pellets that are broader and more diffuse.

634414 SMARTer® Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian 192 Rxns Inquire for Quotation

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.
*

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian improves sequencing performance compared to the original SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, particularly for NextSeq® and MiniSeq™ instruments carrying the two-channel SBS technology. This kit includes the Indexing Primer Set HT for Illumina v2; for your convenience, we also offer the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components (Cat. #s 634418 and 634419) without indexing primers.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of sequencing libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Structural features of final libraries generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. The adapters added using 5' PCR Primer HT and 3' PCR Primer HT contain sequences allowing clustering on any Illumina® flow cell (P7 shown in light blue, P5 shown in red), Illumina TruSeq® HT indexes (Index 1 [i7] sequence shown in orange, and Index 2 [i5] sequence shown in yellow), as well as the regions recognized by sequencing primers Read Primer 2 (Read 2, purple) and Read Primer 1 (Read 1, green). Read 1 generates sequences antisense to the original RNA, while Read 2 yields sequences sense to the original RNA (orientation of original RNA denoted by 5' and 3' in dark blue). The first three nucleotides of the second sequencing read (Read 2) are derived from the Pico v2 SMART Adapter (shown as Xs). These three nucleotides must be trimmed prior to mapping if performing paired-end sequencing.

Back

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing performance with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved pass-filter rates (%PF) with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Libraries generated with the Pico v1 or Pico v2 kits were pooled and run on NextSeq 500 or MiniSeq instruments, as indicated. For each graph, blue boxplots indicate the distribution of cluster densities for unfiltered (i.e., raw) reads, while the green boxplots indicate the distribution of cluster densities for reads that passed filtering. Quantities of reads passing filter (in millions) and %PF values for each sequencing run are included above each graph. The expected number of reads passing filter according to Illumina specifications was 130 million reads for runs on the NextSeq and 25 million reads for runs on the MiniSeq. Proportions of reads that aligned to PhiX sequences ranged from 0.5% to 1.15% for all sequencing runs. As indicated in the graphs, libraries generated with the Pico v2 kit achieved higher %PF values for both Illumina platforms relative to libraries generated with the Pico v1 kit, and yielded quantities of reads passing filter that greatly exceeded the Illumina specifications.

Back

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Workflow for SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Schematic of technology in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. SMART technology is used in this ligation-free protocol to preserve strand-of-origin information. Random priming (represented as the green N6 Primer) allows the generation of cDNA from all RNA fragments in the sample, including rRNA. When the SMARTScribe Reverse Transcriptase (RT) reaches the 5' end of the RNA fragment, the enzyme’s terminal transferase activity adds a few non-templated nucleotides to the 3' end of the cDNA (shown as Xs). The carefully designed Pico v2 SMART Adapter (included in the SMART TSO Mix v2) base-pairs with the non-templated nucleotide stretch, creating an extended template to enable the RT to continue replicating to the end of the oligonucleotide. The resulting cDNA contains sequences derived from the random primer and the Pico v2 SMART Adapter used in the reverse transcription reaction. In the next step, a first round of PCR amplification (PCR1) adds full-length Illumina adapters, including barcodes. The 5' PCR Primer binds to the Pico v2 SMART Adapter sequence (light purple), while the 3' PCR Primer binds to sequence associated with the random primer (green). The ribosomal cDNA (originating from rRNA) is then cleaved by ZapR v2 in the presence of the mammalian-specific R-Probes v2. This process leaves the library fragments originating from non-rRNA molecules untouched, with priming sites available on both 5' and 3' ends for further PCR amplification. These fragments are enriched via a second round of PCR amplification (PCR2) using primers universal to all libraries. The final library contains sequences allowing clustering on any Illumina flow cell.

Back

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sequencing metrics with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

Improved sensitivity and reproducibility with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. Sequencing libraries were generated from 1 ng and 10 ng inputs of total RNA extracted from human lung FFPE tissue using both the Pico v1 and Pico v2 kits, and sequenced on a NextSeq 500 instrument. Panel A. Sequencing metrics for libraries generated from 1 ng or 10 ng inputs using each kit. For both input amounts, the Pico v2 kit resulted in greater library yields, a lower proportion of reads mapping to rRNA and mtRNA, and a lower duplicate rate. For the 1 ng input, sequencing data from the Pico v2 library also identified thousands more transcripts than sequencing data from the Pico v1 library, indicating a higher sensitivity for Pico v2. Panel B. Comparison of transcript expression levels across input amounts. Higher reproducibility was observed between 1 ng and 10 ng inputs for data generated with the Pico v2 kit vs. data generated using the Pico v1 kit. FPKM values are shown on a Log10 scale. Transcripts represented in only one library can be seen along the X- and Y-axes of the scatter plots.

Back

SeqAmp CB PCR buffer improves bead-pellet formation

SeqAmp CB PCR buffer improves bead-pellet formation

Improved bead-pellet formation with new SeqAmp CB PCR buffer. The PCR buffer included in the Pico v2 kit was re-formulated to allow for faster, tighter bead-pellet formation. Following magnetic separation for a fixed period, bead pellets formed in the new SeqAmp CB buffer (right) are tighter than those formed in the original PCR buffer (left). Tighter bead pellets tend to dry more evenly and are easier to resuspend than pellets that are broader and more diffuse.

Back

634414: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian

634414: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian
634417 SMARTer® Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components 48 Rxns USD $3764.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components are used with our SMARTer RNA Unique Dual Indexing Kits (Cat. #s 634451, 634452, and 634457) to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA. This kit incorporates Takara Bio's proprietary SMART (Switching Mechanism at the 5ˈ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian improves sequencing performance compared to the original SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, particularly for NextSeq® and MiniSeq™ instruments carrying the two-channel SBS technology.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634417: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components

634417: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components
634418 SMARTer® Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components 96 Rxns USD $4993.00

License Statement

ID Number  
425 LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
395
This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family.  Additional information may be found at https://www.takarabio.com/patents. 
450 This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components are used with our SMARTer RNA Unique Dual Indexing Kits (Cat. #s 634451, 634452, and 634457) to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg—10 ng inputs of purified total RNA. This kit incorporates Takara Bio's proprietary SMART (Switching Mechanism at the 5ˈ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian improves sequencing performance compared to the original SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, particularly for NextSeq® and MiniSeq™ instruments carrying the two-channel SBS technology.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Documents Components Image Data

Back

634418: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components

634418: SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components

*You must be logged in to a Purchasing Account in order to purchase these products online, since the purchase of these products may be restricted depending on your account type. Researchers at not-for-profit accounts receive a limited use license with their purchase of the product. Researchers at for-profit accounts must obtain a license prior to purchase. For details please contact licensing@takarabio.com.

Overview

  • Accommodates picogram inputs of starting material—Start from 250 pg–10 ng of total RNA from human, mouse, or rat.
  • Versatile—Generate reproducible data from RNA of any quality (including FFPE and LCM samples and cell-free RNA).
  • Improved sequencing performance—Achieve a high percentage of clusters passing filter (%PF) without adding PhiX and identify more transcripts with fewer duplicates.
  • Strand information—Identify each transcript’s strand of origin with very high accuracy.
  • Fast, streamlined protocol—Go from start to finish in ~6 hours and save time during library purification with an improved buffer formulation.
  • Seamless integration with Illumina sequencing—Generate Illumina-ready libraries with up to 192 combinations of indexes.

Interested in more data and FAQs about this product? Visit the NGS Learning Center.

More Information

Applications

  • Robust NGS library construction that retains strand information
  • Use for RNA-seq on all Illumina platforms
  • Captures coding and noncoding information from total mammalian RNA of any quality, including RNA obtained from FFPE samples

Additional product information

Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.


Powered by Bioz See more details on Bioz
Powered by Bioz See more details on Bioz

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2025 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

Takara Bio

Takara Bio USA, Inc. provides kits, reagents, instruments, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, Takara Bio USA is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology. Our mission is to develop high-quality innovative tools and services to accelerate discovery.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES (EXCEPT AS SPECIFICALLY NOTED).

Support
  • Contact us
  • Technical support
  • Customer service
  • Shipping & delivery
  • Sales
  • Feedback
Products
  • New products
  • Special offers
  • Instrument & reagent services
Learning centers
  • NGS
  • Gene function
  • Stem cell research
  • Protein research
  • PCR
  • Cloning
  • Nucleic acid purification
About
  • Our brands
  • Careers
  • Events
  • Blog
  • Need help?
  • Announcements
  • Quality and compliance
  • That's Good Science!
Facebook Twitter  LinkedIn

logo strip white

©2025 Takara Bio Inc. All Rights Reserved.

Region - North America Privacy Policy Terms and Conditions Terms of Use

Top



  • COVID-19 research
  • Viral detection with qPCR
  • SARS-CoV-2 pseudovirus
  • Human ACE2 stable cell line
  • Viral RNA isolation
  • Viral and host sequencing
  • Vaccine development
  • CRISPR screening
  • Drug discovery
  • Immune profiling
  • Publications
  • Next-generation sequencing
  • Spatial omics
  • RNA-seq
  • DNA-seq
  • Single-cell NGS automation
  • Reproductive health
  • Bioinformatics tools
  • Immune profiling
  • Real-time PCR
  • Great value master mixes
  • Signature enzymes
  • High-throughput real-time PCR solutions
  • Detection assays
  • References, standards, and buffers
  • Stem cell research
  • Media, differentiation kits, and matrices
  • Stem cells and stem cell-derived cells
  • mRNA and cDNA synthesis
  • In vitro transcription
  • cDNA synthesis kits
  • Reverse transcriptases
  • RACE kits
  • Purified cDNA & genomic DNA
  • Purified total RNA and mRNA
  • PCR
  • Most popular polymerases
  • High-yield PCR
  • High-fidelity PCR
  • GC rich PCR
  • PCR master mixes
  • Cloning
  • In-Fusion seamless cloning
  • Competent cells
  • Ligation kits
  • Restriction enzymes
  • Nucleic acid purification
  • Automated platforms
  • Plasmid purification kits
  • Genomic DNA purification kits
  • DNA cleanup kits
  • RNA purification kits
  • Gene function
  • Gene editing
  • Viral transduction
  • Fluorescent proteins
  • T-cell transduction and culture
  • Tet-inducible expression systems
  • Transfection reagents
  • Cell biology assays
  • Protein research
  • Purification products
  • Two-hybrid and one-hybrid systems
  • Mass spectrometry reagents
  • Antibodies and ELISAs
  • Primary antibodies and ELISAs by research area
  • Fluorescent protein antibodies
  • New products
  • Special offers
  • OEM
  • Portfolio
  • Process
  • Facilities
  • Request samples
  • FAQs
  • Instrument services
  • Apollo services
  • ICELL8 services
  • SmartChip ND system services
  • Gene and cell therapy manufacturing services
  • Services
  • Facilities
  • Our process
  • Resources
  • Customer service
  • Sales
  • Make an appointment with your sales rep
  • Shipping & delivery
  • Technical support
  • Feedback
  • Online tools
  • GoStix Plus FAQs
  • Partnering & Licensing
  • Vector information
  • Vector document overview
  • Vector document finder
Takara Bio's award-winning GMP-compliant manufacturing facility in Kusatsu, Shiga, Japan.

Partner with Takara Bio!

Takara Bio is proud to offer GMP-grade manufacturing capabilities at our award-winning facility in Kusatsu, Shiga, Japan.

  • Automation systems
  • Shasta Single Cell System introduction
  • SmartChip Real-Time PCR System introduction
  • ICELL8 introduction
  • Next-generation sequencing
  • RNA-seq
  • Technical notes
  • Technology and application overviews
  • FAQs and tips
  • DNA-seq protocols
  • Bioinformatics resources
  • Webinars
  • Spatial biology
  • Real-time PCR
  • Download qPCR resources
  • Overview
  • Reaction size guidelines
  • Guest webinar: extraction-free SARS-CoV-2 detection
  • Technical notes
  • Nucleic acid purification
  • Nucleic acid extraction webinars
  • Product demonstration videos
  • Product finder
  • Plasmid kit selection guide
  • RNA purification kit finder
  • mRNA and cDNA synthesis
  • mRNA synthesis
  • cDNA synthesis
  • PCR
  • Citations
  • PCR selection guide
  • Technical notes
  • FAQ
  • Cloning
  • Automated In-Fusion Cloning
  • In-Fusion Cloning general information
  • Primer design and other tools
  • In‑Fusion Cloning tips and FAQs
  • Applications and technical notes
  • Stem cell research
  • Overview
  • Protocols
  • Technical notes
  • Gene function
  • Gene editing
  • Viral transduction
  • T-cell transduction and culture
  • Inducible systems
  • Cell biology assays
  • Protein research
  • Capturem technology
  • Antibody immunoprecipitation
  • His-tag purification
  • Other tag purification
  • Expression systems
  • Antibodies and ELISA
  • Molecular diagnostics
  • Interview: adapting to change with Takara Bio
  • Applications
  • Solutions
  • Partnering
  • Contact us
  • mRNA and protein therapeutics
  • Characterizing the viral genome and host response
  • Identifying and cloning protein targets
  • Expressing and purifying protein targets
  • Immunizing mice and optimizing vaccines
  • Pathogen detection
  • Sample prep
  • Detection methods
  • Identification and characterization
  • SARS-CoV-2
  • Antibiotic-resistant bacteria
  • Food crop pathogens
  • Waterborne disease outbreaks
  • Viral-induced cancer
  • Immunotherapy research
  • T-cell therapy
  • Antibody therapeutics
  • T-cell receptor profiling
  • TBI initiatives in cancer therapy
  • Cancer research
  • Kickstart your cancer research with long-read sequencing
  • Sample prep from FFPE tissue
  • Sample prep from plasma
  • Cancer biomarker quantification
  • Single cancer cell analysis
  • Cancer transcriptome analysis
  • Cancer genomics and epigenomics
  • HLA typing in cancer
  • Gene editing for cancer therapy/drug discovery
  • Alzheimer's disease research
  • Antibody engineering
  • Sample prep from FFPE tissue
  • Single-cell sequencing
  • Reproductive health technologies
  • Embgenix FAQs
  • Preimplantation genetic testing
  • ESM partnership program
  • ESM Collection Kit forms
  • Infectious diseases
  • Develop vaccines for HIV
Create a web account with us

Log in to enjoy additional benefits

Want to save this information?

An account with takarabio.com entitles you to extra features such as:

•  Creating and saving shopping carts
•  Keeping a list of your products of interest
•  Saving all of your favorite pages on the site*
•  Accessing restricted content

*Save favorites by clicking the star () in the top right corner of each page while you're logged in.

Create an account to get started

  • BioView blog
  • Automation
  • Cancer research
  • Career spotlights
  • Current events
  • Customer stories
  • Gene editing
  • Research news
  • Single-cell analysis
  • Stem cell research
  • Tips and troubleshooting
  • Women in STEM
  • That's Good Support!
  • About our blog
  • That's Good Science!
  • SMART-Seq Pro Biomarker Discovery Contest
  • DNA extraction educational activity
  • That's Good Science Podcast
  • Season one
  • Season two
  • Season three
  • Our brands
  • Our history
  • In the news
  • Events
  • Biomarker discovery events
  • Calendar
  • Conferences
  • Speak with us
  • Careers
  • Company benefits
  • Trademarks
  • License statements
  • Quality statement
  • HQ-grade reagents
  • International Contacts by Region
  • United States and Canada
  • China
  • Japan
  • Korea
  • Europe
  • India
  • Affiliates & distributors
  • Need help?
  • Privacy request
  • Website FAQs

That's GOOD Science!

What does it take to generate good science? Careful planning, dedicated researchers, and the right tools. At Takara Bio, we thoughtfully develop exceptional products to tackle your most challenging research problems, and have an expert team of technical support professionals to help you along the way, all at superior value.

Explore what makes good science possible

 Customer Login
 View Cart (0)
Takara Bio
  • Home
  • Products
  • Services & Support
  • Learning centers
  • APPLICATIONS
  • About
  • Contact Us
  •  Customer Login
  • Register
  •  View Cart (0)

Takara Bio USA, Inc. provides kits, reagents, instruments, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, Takara Bio USA is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology. Our mission is to develop high-quality innovative tools and services to accelerate discovery.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES (EXCEPT AS SPECIFICALLY NOTED).

Clontech, TaKaRa, cellartis

  • Products
  • COVID-19 research
  • Next-generation sequencing
  • Real-time PCR
  • Stem cell research
  • mRNA and cDNA synthesis
  • PCR
  • Cloning
  • Nucleic acid purification
  • Gene function
  • Protein research
  • Antibodies and ELISA
  • New products
  • Special offers
  • COVID-19 research
  • Viral detection with qPCR
  • SARS-CoV-2 pseudovirus
  • Human ACE2 stable cell line
  • Viral RNA isolation
  • Viral and host sequencing
  • Vaccine development
  • CRISPR screening
  • Drug discovery
  • Immune profiling
  • Publications
  • Next-generation sequencing
  • Spatial omics
  • RNA-seq
  • DNA-seq
  • Single-cell NGS automation
  • Reproductive health
  • Bioinformatics tools
  • Immune profiling
  • Real-time PCR
  • Great value master mixes
  • Signature enzymes
  • High-throughput real-time PCR solutions
  • Detection assays
  • References, standards, and buffers
  • Stem cell research
  • Media, differentiation kits, and matrices
  • Stem cells and stem cell-derived cells
  • mRNA and cDNA synthesis
  • In vitro transcription
  • cDNA synthesis kits
  • Reverse transcriptases
  • RACE kits
  • Purified cDNA & genomic DNA
  • Purified total RNA and mRNA
  • PCR
  • Most popular polymerases
  • High-yield PCR
  • High-fidelity PCR
  • GC rich PCR
  • PCR master mixes
  • Cloning
  • In-Fusion seamless cloning
  • Competent cells
  • Ligation kits
  • Restriction enzymes
  • Nucleic acid purification
  • Automated platforms
  • Plasmid purification kits
  • Genomic DNA purification kits
  • DNA cleanup kits
  • RNA purification kits
  • Gene function
  • Gene editing
  • Viral transduction
  • Fluorescent proteins
  • T-cell transduction and culture
  • Tet-inducible expression systems
  • Transfection reagents
  • Cell biology assays
  • Protein research
  • Purification products
  • Two-hybrid and one-hybrid systems
  • Mass spectrometry reagents
  • Antibodies and ELISA
  • Primary antibodies and ELISAs by research area
  • Fluorescent protein antibodies
  • Services & Support
  • OEM
  • Instrument services
  • Gene and cell therapy manufacturing
  • Customer service
  • Sales
  • Shipping & delivery
  • Technical support
  • Feedback
  • Online tools
  • Partnering & Licensing
  • Vector information
  • OEM
  • Portfolio
  • Process
  • Facilities
  • Request samples
  • FAQs
  • Instrument services
  • Apollo services
  • ICELL8 services
  • SmartChip ND system services
  • Gene and cell therapy manufacturing
  • Services
  • Facilities
  • Our process
  • Resources
  • Sales
  • Make an appointment with your sales rep
  • Online tools
  • GoStix Plus FAQs
  • Vector information
  • Vector document overview
  • Vector document finder
  • Learning centers
  • Automation systems
  • Next-generation sequencing
  • Spatial biology
  • Real-time PCR
  • Nucleic acid purification
  • mRNA and cDNA synthesis
  • PCR
  • Cloning
  • Stem cell research
  • Gene function
  • Protein research
  • Antibodies and ELISA
  • Automation systems
  • Shasta Single Cell System introduction
  • SmartChip Real-Time PCR System introduction
  • ICELL8 introduction
  • Next-generation sequencing
  • RNA-seq
  • Technical notes
  • Technology and application overviews
  • FAQs and tips
  • DNA-seq protocols
  • Bioinformatics resources
  • Webinars
  • Real-time PCR
  • Download qPCR resources
  • Overview
  • Reaction size guidelines
  • Guest webinar: extraction-free SARS-CoV-2 detection
  • Technical notes
  • Nucleic acid purification
  • Nucleic acid extraction webinars
  • Product demonstration videos
  • Product finder
  • Plasmid kit selection guide
  • RNA purification kit finder
  • mRNA and cDNA synthesis
  • mRNA synthesis
  • cDNA synthesis
  • PCR
  • Citations
  • PCR selection guide
  • Technical notes
  • FAQ
  • Cloning
  • Automated In-Fusion Cloning
  • In-Fusion Cloning general information
  • Primer design and other tools
  • In‑Fusion Cloning tips and FAQs
  • Applications and technical notes
  • Stem cell research
  • Overview
  • Protocols
  • Technical notes
  • Gene function
  • Gene editing
  • Viral transduction
  • T-cell transduction and culture
  • Inducible systems
  • Cell biology assays
  • Protein research
  • Capturem technology
  • Antibody immunoprecipitation
  • His-tag purification
  • Other tag purification
  • Expression systems
  • APPLICATIONS
  • Molecular diagnostics
  • mRNA and protein therapeutics
  • Pathogen detection
  • Immunotherapy research
  • Cancer research
  • Alzheimer's disease research
  • Reproductive health technologies
  • Infectious diseases
  • Molecular diagnostics
  • Interview: adapting to change with Takara Bio
  • Applications
  • Solutions
  • Partnering
  • Contact us
  • mRNA and protein therapeutics
  • Characterizing the viral genome and host response
  • Identifying and cloning protein targets
  • Expressing and purifying protein targets
  • Immunizing mice and optimizing vaccines
  • Pathogen detection
  • Sample prep
  • Detection methods
  • Identification and characterization
  • SARS-CoV-2
  • Antibiotic-resistant bacteria
  • Food crop pathogens
  • Waterborne disease outbreaks
  • Viral-induced cancer
  • Immunotherapy research
  • T-cell therapy
  • Antibody therapeutics
  • T-cell receptor profiling
  • TBI initiatives in cancer therapy
  • Cancer research
  • Kickstart your cancer research with long-read sequencing
  • Sample prep from FFPE tissue
  • Sample prep from plasma
  • Cancer biomarker quantification
  • Single cancer cell analysis
  • Cancer transcriptome analysis
  • Cancer genomics and epigenomics
  • HLA typing in cancer
  • Gene editing for cancer therapy/drug discovery
  • Alzheimer's disease research
  • Antibody engineering
  • Sample prep from FFPE tissue
  • Single-cell sequencing
  • Reproductive health technologies
  • Embgenix FAQs
  • Preimplantation genetic testing
  • ESM partnership program
  • ESM Collection Kit forms
  • Infectious diseases
  • Develop vaccines for HIV
  • About
  • BioView blog
  • That's Good Science!
  • Our brands
  • Our history
  • In the news
  • Events
  • Careers
  • Trademarks
  • License statements
  • Quality and compliance
  • HQ-grade reagents
  • International Contacts by Region
  • Need help?
  • Website FAQs
  • BioView blog
  • Automation
  • Cancer research
  • Career spotlights
  • Current events
  • Customer stories
  • Gene editing
  • Research news
  • Single-cell analysis
  • Stem cell research
  • Tips and troubleshooting
  • Women in STEM
  • That's Good Support!
  • About our blog
  • That's Good Science!
  • SMART-Seq Pro Biomarker Discovery Contest
  • DNA extraction educational activity
  • That's Good Science Podcast
  • Season one
  • Season two
  • Season three
  • Events
  • Biomarker discovery events
  • Calendar
  • Conferences
  • Speak with us
  • Careers
  • Company benefits
  • International Contacts by Region
  • United States and Canada
  • China
  • Japan
  • Korea
  • Europe
  • India
  • Affiliates & distributors
  • Need help?
  • Privacy request
Takara Bio
  • Products
  • Services & Support
  • Learning centers
  • APPLICATIONS
  • About
  • Contact Us